Olaparib in BRCA-mutated, HER-2 negative metastatic breast cancer
Olaparib significantly prolonged progression-free survival compared to chemotherapy, particularly in
Menu
CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and pertuzumab, triggers sustained senescence: new data from a Michelangelo Foundation study.
Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did not increase the rate of pathological complete remission, mostly influenced by PD-L1 expression.
NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as neoadjuvant therapy, with a relevant effect on Ki67
Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a review published on Nature Reviews – Clinical Oncology highlights the state of the art therapy in triple-negative breast cancer
Olaparib significantly prolonged progression-free survival compared to chemotherapy, particularly in
This multicentric machine learning model improves performance of local models
Foundation’s experts and data in key educational sessions to share
Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a
NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as
Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did
CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and
Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did
NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as
Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a
Foundation’s experts and data in key educational sessions to share
This multicentric machine learning model improves performance of local models
